Skip to main content
Clinical Trials/NCT03508492
NCT03508492
Unknown
Not Applicable

Comparative Study to Asses the Satisfaction With Tinted Chlorhexidine Applicators (Chloraprep® and Nex Clorex 2%)

Cristina Fernandez Perez0 sites22 target enrollmentApril 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Satisfaction
Sponsor
Cristina Fernandez Perez
Enrollment
22
Primary Endpoint
Surgeon's global satisfaction with the applicators.
Last Updated
8 years ago

Overview

Brief Summary

The development of surgical site infections (SSI) in clean-contaminated surgery is regarded as being preventable. Known to be effective in the prevention of surgical site infection are the adequate sterilization of the surgical instruments, asepsis during operation, antibiotic prophylaxis where indicated, and certainly the preparation of the skin at the incision site. During the last decades the use of alcoholic chlorhexidine has replaced povidone iodine for preoperative skin preparation. In order to improve the way alcoholic chlorhexidine is applied, pharmaceutical industry has developed new applicators.

This randomized study was conducted to know the surgeons' satisfaction within the use of two tinted applicators: Chloraprep® and Nex Clorex 2%

Registry
clinicaltrials.gov
Start Date
April 2018
End Date
June 2018
Last Updated
8 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Sponsor
Cristina Fernandez Perez
Responsible Party
Sponsor Investigator
Principal Investigator

Cristina Fernandez Perez

Head of Preventive and Public Health Department

Hospital San Carlos, Madrid

Eligibility Criteria

Inclusion Criteria

  • Volunteer surgeons from colon, cardiac, knee and hip surgical departments. Once surgeon has enrolled the study, patients will be selected if they have hospital admission with scheduled surgery and have signed informed consent

Exclusion Criteria

  • Urgent surgeries
  • Outpatient surgery
  • Surgical complex cures
  • Mixed interventions: exploratory or sequential
  • Unscheduled surgeries
  • Rejection of participation
  • Chlorhexidine or isopropyl alcohol hypersensibility patients
  • If any patients changed its mind after signing the informed consent will be removed from the study.

Outcomes

Primary Outcomes

Surgeon's global satisfaction with the applicators.

Time Frame: Intraoperative

Using an analog visual scale we will record the total score, over a maximum of 80 points, that assess the following quality aspects of the applicators: * Satisfaction with the presentation of the product * Satisfaction with the simplicity of activation * Satisfaction with the mix of the different components of the product * Satisfaction with the comfort of product use * Satisfaction with the surface covered by an applicator * Satisfaction with the shape of the applicator for painting areas of difficult access * Satisfaction with the drying time of the product * Satisfaction with the area delimited with the use of the product

Qualities of each applicators

Time Frame: Intraoperative

Using an analog visual scale, were one end represents "totally disagree" and the other "totally agree" (0-10 points), we will record the score of each of the following quality aspects of the applicators: * Satisfaction with the presentation of the product * Satisfaction with the simplicity of activation * Satisfaction with the mix of the different components of the product * Satisfaction with the comfort of product use * Satisfaction with the surface covered by an applicator * Satisfaction with the shape of the applicator for painting areas of difficult access * Satisfaction with the drying time of the product * Satisfaction with the area delimited with the use of the product

Secondary Outcomes

  • Surgical site infection incidence(During the first 30 to 90 days after surgery, according to the SSI prevention protocol)
  • Costs of using the applicators(Through study completion, an average of 3 months)
  • Adhesion to preoperative measures to avoid surgical site infections (SSI)(Through study completion, an average of 3 months)

Similar Trials